Company intelligence / Profile preview
Cothera Bioscience
San Francisco, California, United Statescotherabio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
PC-002 received FDA Fast Track Designation for Burkitt Lymphoma in October 2024. The company will present clinical results from the PC002-01 trial at the 2024 American Society of Hematology annual meeting.
- Therapeutic areas
- Oncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Beyond the preview
Go deeper on Cothera Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cothera Bioscience.